XML 14 R3.htm IDEA: XBRL DOCUMENT v3.25.1
Condensed Consolidated Statements of Operations - USD ($)
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenues:    
Revenue from collaborative arrangements $ 65,343 $ 0
Operating expenses:    
Research and development 16,090,902 20,913,790
General and administrative 9,024,970 10,571,179
Total operating expenses 25,115,872 31,484,969
Loss from operations (25,050,529) (31,484,969)
Other income (expense):    
Interest income 808,077 1,500,290
Interest expense 0 (177,833)
Change in fair value of common stock warrant liability 3,712,872 0
Gain (loss) on investment in affiliated entity 695,131 (126,018)
Net unrealized gain on available-for-sale equity securities 140,234 500,877
Other expense, net (482) (682,218)
Net loss $ (19,694,697) $ (30,469,871)
Net loss per share    
Basic (in dollars per share) $ (0.51) $ (1.31)
Diluted (in dollars per share) $ (0.51) $ (1.31)
Weighted average number of common shares used to compute net loss per share    
Basic (in shares) 38,613,653 23,291,512
Diluted (in shares) 38,613,653 23,291,512